SYNthesis BioVentures is a fund focused on early-stage therapeutics, investing in projects from discovery through preclinical proof of concept and IND enabling studies.
Originally engaged to manage the announcement and media launch of SYNthesis BioVentures’ FDA approval, narrative now works with the team to provide ongoing PR assistance.